Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05741723 · ClinicalTrials.gov registry record
OCS DCD Heart + CAP Continued Follow-Up
A clinical trial of Heart Transplant, sponsored by TransMedics.
- Active
- Registry status
- 276
- Enrollment target
- 20
- Study locations
NCT05741723: Active study of Heart Transplant, sponsored by TransMedics.
NCT05741723 is a study of Heart Transplant that is active but no longer recruiting, run by TransMedics. The registered enrollment target is 276 participants, below the 8,507-participant average among 12 other Heart Transplant trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05741723, a study of Heart Transplant, is active but no longer recruiting, sponsored by TransMedics.
- ACTIVE NOT RECRUITING
- Registry status
- 276 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this post-approval study is to evaluate long-term outcomes of patients enrolled in the OCS DCD Heart and OCS DCD Heart CAP studies.
Primary Outcome
Patient survival through 5 years post-transplant
Conditions Studied
Interventions
- DEVICE OCS Heart
Study Locations (20)
California
- University of California San Diago - La Jolla
- Stanford University - Palo Alto
Florida
- Mayo Clinic Florida - Jacksonville
- AdventHealth Orlando - Orlando
Massachusetts
- Tufts Medical Center - Boston
- Massachusetts General Hospital - Boston
Minnesota
- Minneapolis Heart Institute - Minneapolis
- University of Minnesota - Minneapolis
New York
- Nyph/Cumc - New York
- Montefiore - The Bronx
Wisconsin
- University of Wisconsin - Madison
- Froedtert & the Medical College of Wisconsin - Milwaukee
Connecticut
- Yale New Haven Hospital - New Haven
Georgia
- Emory University Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2019-11-26 |
| Est. Completion | 2026-10 |
What the registry record for NCT05741723 still lists
NCT05741723 is an observational study that tracks outcomes without assigning an intervention. The registered 276 participants enrollment target is mid-sized for trials with a published cap, below the 8,507-participant average among 12 other Heart Transplant trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Heart Transplant appearing as the primary indexed condition, and to 1 intervention - of which OCS Heart is the first listed.
NCT05741723 names 20 study sites across 14 states, led by California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05741723 about?
NCT05741723 is a clinical study titled "OCS DCD Heart + CAP Continued Follow-Up". The objective of this post-approval study is to evaluate long-term outcomes of patients enrolled in the OCS DCD Heart and OCS DCD Heart CAP studies.
What is the current status of trial NCT05741723?
This trial is currently active not recruiting. The enrollment target is 276 participants. The study started on 2019-11-26. Estimated completion is 2026-10.
What conditions does trial NCT05741723 study?
This clinical trial studies the following conditions: Heart Transplant.
What interventions are being tested in trial NCT05741723?
The interventions under investigation include: OCS Heart (DEVICE).
Who is sponsoring clinical trial NCT05741723?
This trial is sponsored by TransMedics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05741723 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05741723's enrollment target sits among peer trials
276 4th of 12 higher than 9 of 12 other Heart Transplant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
US National OCS Heart Perfusion (OHP) Registry
RECRUITING
-
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
RECRUITING · NA
-
Belatacept in Heart Transplantation
RECRUITING · Phase 2
-
Enhancing Heart Allograft Function With the OCS Heart System Trial
RECRUITING · NA
-
Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01371630 · 276 participants · Phase 1
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- NCT04192344 · 276 participants · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
- NCT05294991 · 276 participants · NA
Wellness App for Sleep Disturbance in Hematological Cancer Patients
- NCT05610852 · 276 participants · NA
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI